文献速递前列腺癌

基因组风险预测前列腺癌分子影像检测的转移性淋巴结病变

Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2019-01-15

研究纳入91例同时具有Decipher基因组分类器(GC)评分和治疗前68Ga-PSMA-11 PET扫描的前列腺癌患者,评估GC评分是否预测PSMA阳性淋巴结病变。结果显示GC评分每增加0.1单位,盆腔淋巴结受累风险增加约40%,但与骨转移无显著关联。作者认为GC高风险患者可能受益于更多淋巴结影像检查和治疗强化。

要点

  • GC评分每增加0.1单位,盆腔淋巴结受累的比值比增加约40%。
  • GC评分与PSMA阳性骨转移无显著关联。
  • 作者建议GC高风险患者可考虑更积极的淋巴结影像和治疗强化。

核心结论

  • GC评分每增加0.1单位,PSMA阳性淋巴结受累的比值增加约40%。
  • GC高风险患者可能受益于更多淋巴结影像检查和治疗强化,包括盆腔淋巴结清扫、盆腔淋巴结放疗和/或联合化疗激素药物。

研究设计与样本

  • 研究纳入2015年12月至2018年9月间91例同时具有GC评分和治疗前68Ga-PSMA-11 PET扫描的前列腺癌患者。
  • 使用NCCN、CAPRA和GC评分进行风险分层。
  • 采用逻辑回归分析与PSMA阳性疾病相关的因素。

主要发现

  • NCCN标准将23例(25.3%)和68例(74.7%)分别归为中危和高危。
  • CAPRA评分将28例(30.8%)和63例(69.2%)分别归为低/中危和高危。
  • 仅45例(49.4%)具有GC高风险评分。
  • 27例(29.7%)发现PSMA阳性的盆腔淋巴结受累。
  • GC评分较高与盆腔淋巴结受累显著相关(OR 1.38每0.1单位;p=0.009),与任何PSMA阳性淋巴结受累(盆腔或远处)显著相关(OR 1.40每0.1单位;p=0.007)。

临床怎么用

  • 作者认为GC高风险患者可能受益于更多淋巴结影像检查和治疗强化,可能通过盆腔淋巴结清扫、盆腔淋巴结放疗和/或联合化疗激素药物实现。

局限性

  • 选择偏倚,仅纳入能够接受两种检查的患者。
  • 样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Decipher genomic classifier (GC) is increasingly being used to determine metastasis risk in men with localized prostate cancer (PCa). Whether GCs predict for the presence of occult metastatic disease at presentation or subsequent metastatic progression is unknown. OBJECTIVE: To determine if GC scores predict extraprostatic 68Ga prostate-specific membrane antigen (68Ga-PSMA-11) positron emission tomography (PET) positivity at presentation. DESIGN, SETTING, AND PARTICIPANTS: Between December 2015 and September 2018, 91 PCa patients with both GC scores and pretreatment 68Ga-PSMA-11 PET scans were identified. Risk stratification was performed using the National Comprehensive Cancer Network (NCCN), Cancer of the Prostate Risk Assessment (CAPRA), and GC scores. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic regression was used to identify factors correlated with PSMA-positive disease. RESULTS AND LIMITATIONS: The NCCN criteria identified 23 (25.3%) and 68 patients (74.7%) as intermediate and high risk, while CAPRA scores revealed 28 (30.8%) and 63 (69.2%) as low/intermediate and high risk, respectively. By contrast, only 45 patients (49.4%) had high-risk GC scores. PSMA-avid pelvic nodal involvement was identified in 27 patients (29.7%). Higher GC score was significantly associated with pelvic nodal involvement (odds ratio [OR] 1.38 per 0.1 units; p=0.009) and any PSMA-avid nodal involvement (pelvic or distant; OR 1.40 per 0.1 units; p=0.007). However, higher GC score was not significantly associated with PSMA-avid osseous metastases (OR 1.11 per 0.1 units; p=0.50). Limitations include selection bias for patients able to receive both tests and the sample size. CONCLUSIONS: Each 0.1-unit increase in GC score was associated with an approximate 40% increase in the odds of PSMA-avid lymph node involvement. These data suggest that patients with GC high risk might benefit from more nodal imaging and treatment intensification, potentially via pelvic nodal dissection, pelvic nodal irradiation, and/or the addition of chemohormonal agents. PATIENT SUMMARY: Patients with higher genomic classifier scores were found to have more metastatic lymph node involvement on prostate-specific membrane antigen imaging.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Xu MJ, Kornberg Z, Gadzinski AJ, et al. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31411984. doi:10.1016/j.euo.2018.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。